Nuvo is honored to have been named to TIME's Best Inventions 2024 list of 200 innovations changing how we live.

To compile this year's list, TIME solicited nominations from TIME editors and correspondents around the world, and through an online application process, paying special attention to growing fields—such as health care, AI, and green energy. TIME then evaluated each contender on a number of key factors, including originality, efficacy, ambition, and impact.

Of the new list, TIME’s editors write: “The result is a list of 200 groundbreaking inventions (and 50 special mention inventions)—including the world's largest computer chip, a humanoid robot joining the workforce, and a bioluminescent houseplant—that are changing how we live, work, play, and think about what’s possible.”

See the full list here: time.com/best-inventions-2024

‍

This article originally appeared in HIT Consultant: https://hitconsultant.net/2024/10/03/prenatal-monitoring-remote-technology-provision-of-care/

‍

The Evolution of Prenatal Monitoring: How AI and Remote Monitoring Can Improve the Provision of Care

by Amit Reches, CTO, Nuvo Group 10/03/2024

Prenatal monitoring technology has advanced considerably over the last decade. High-resolution sonograms now offer unprecedented clarity, enabling detailed insights into fetal development. Meanwhile, innovations have transformed previously cumbersome and uncomfortable equipment into more portable and user-friendly devices, enhancing accessibility and patient comfort. However, for essential insights into fetal health and development, clinicians still rely primarily on legacy in-clinic systems and techniques, such as cardiotocography (CTG), which possess inherent challenges.

Current Challenges with Legacy Systems

The non-stress test (NST), measuring maternal-fetal heart rate and uterine activity, remains the cornerstone of prenatal monitoring. This has traditionally entailed the use of CTG, requiring frequent visits to the clinic where monitoring is performed using technology that has changed little since it was first introduced in the 1950s.

It is well-known among clinicians that CTG can require frequent adjustments from the clinical staff to ensure the fetal heart rate trace is maintained. Additionally, NSTs create logistical pressures and burdens regarding patient flow and scheduling. Most significantly, the one-to-two weekly NSTs recommended by the American College of Obstetricians and Gynecologists for the last eight weeks of pregnancy can put additional strain on patients financially, professionally, and personally. This can lead to poor patient compliance, resulting in suboptimal pregnancy management and risk of reduced health outcomes.

Meanwhile, as maternity care deserts continue to expand across the U.S., compounded by a chronic shortage of OB-GYNs and midwives, access to pregnancy care continues to become more challenging.

This situation is beginning to change, with the integration of new technologies that have the potential to enhance the accuracy of maternal-fetal monitoring and increase access to quality prenatal care.

Recent Advancements

The advent of telemedicine and remote patient monitoring over the last four decades has seen increased attention given to prenatal care innovation, with a number of companies attempting to make an impact in the space. Some players are leveraging existing technologies (including CTG), relying on the current standard of care and bringing it into the home. While adding some convenience, such solutions will still suffer from the preexisting requirements and inefficiencies of legacy systems.

Others are looking to employ newer advanced sensing technologies, including electrocardiography (ECG) and electrohysterography (EHG), which can overcome many of the inherent disadvantages associated with CTG. Meanwhile, new concepts of data collection, involving multiple synchronized wearable devices, have emerged to further move the industry forward, enabling providers to scale up monitoring sessions with the same number of clinicians.

Remote pregnancy monitoring thus has the potential to substantially improve the delivery of prenatal care and pregnancy outcomes, by democratizing care and increasing patient compliance.

The Need for Innovation in Cardiac Pregnancy Monitoring

Undetected fetal cardiac abnormalities play a significant role in perinatal outcomes. Moreover, with the maternal mortality crisis, greater attention to maternal cardiac health is also critical to improving outcomes. However, current tools to monitor fetal cardiac function are limited. They can only be performed in-clinic with devices such as echocardiograms and, where applicable, electrocardiography, which must then be interpreted by specialists.

With the general shift to home-based healthcare, there is an obvious need to provide remote access to medical-grade capabilities, enabling expectant mothers to maintain compliance and access essential care beyond the confines of healthcare facilities.

A remote solution based on a combination of technologies, such as non-invasive ECG and phonocardiography (PCG), can provide a detailed analysis of the structure and function of the fetal heart, providing a more complete picture than is currently available. It can also more accurately distinguish between the maternal and fetal heart rates to further improve the management of high-risk pregnancies and enable more timely intervention.

Staying Ahead of the Curve

The wealth of data generated from connected devices can support clinical decision-making and improve efficiency. However, this can also create a new bottleneck, with the same limited number of physicians now being asked to handle a greater workload, with exponentially more data in need of analysis.

Efforts are already underway to develop clinical decision support systems that can enhance efficiency and workflow by automating the review process based on existing guidelines. As technology continues to progress, these systems will leverage machine learning models to further streamline the review process and improve clinical decision-making.

In Steps AI

Already integrated across many healthcare disciplines, artificial intelligence has considerable potential to improve prenatal monitoring. Recently, significant advancements in AI have been made through leveraging foundation models, most notably large language models (LLMs) trained on vast amounts of data. Similar foundation models are now being applied to more diverse types of data, including physiological data such as ECG. Once calibrated to specific datasets, they can be used to perform essential tasks, such as diagnosing and even predicting previously undetectable high-risk cases in pregnancy monitoring.

This approach has the potential to dramatically improve the use of AI in medicine, by transitioning from the current foundation models to a new generation of domain-specific models requiring much smaller datasets. This new era of AI will prioritize the most informative data, enabling more precise and predictive prenatal care.

A Better Future for All

The evolution of prenatal monitoring, from outdated in-clinic systems to advanced remote capabilities, heralds a new era of more accessible and effective patient-centric care. Meanwhile, the introduction of new remote monitoring capabilities, enhanced by next-generation AI models, can address the growing challenges impacting maternity care. Through continued innovation and integration of new technologies, we can look forward to a future of improved outcomes for mothers and babies worldwide.

About Amit Reches

Amit Reches is chief technology officer of Nuvo Group, a company that is closing the gap in health disparities and social determinants of health with advanced pregnancy monitoring technology. Amit is an experienced research and development executive in the field of medical devices, with extensive experience leading multidisciplinary R&D teams. Prior to joining Nuvo Group, he served as VP R&D at Firefly Neuroscience, developer of a brain-mapping technology to improve outcomes associated with mental illnesses, and in various roles as an R&D team leader and researcher prior to that. Amit holds a PhD in Neuroscience from the Technion – Israel Institute of Technology and a BSc in Computer Science from Tel Aviv University.

‍

TEL AVIV, Israel, September 26, 2024 -- Holdco Nuvo GroupD.G Ltd (“Nuvo”), a pioneer in remote pregnancy monitoring, filed a motion onSeptember 10, 2024 to retain Intrepid Investment Bankers (“Intrepid”) to act asits investment banker for the process of exploring and reviewing strategicalternatives as part of its ongoing Chapter 11 process pending before theUnited States Bankruptcy Court for the District of Delaware (the “BankruptcyCourt”).

“We are committed to evaluating a range of strategic optionsto maximize value for our stakeholders,” said Rice Powell, Chief ExecutiveOfficer of Nuvo. “As part of this effort, our Board of Directors has approved theretention of certain legal and financial advisors, including Intrepid, and isfocused on achieving an efficient outcome that will allow for the continueddevelopment and distribution of the Nuvo pregnancy monitoring system forpatients and providers.”

Nuvo intends to continue to manage and operate its businessunder the jurisdiction of the Bankruptcy Court and in accordance with theapplicable provisions of the Bankruptcy Code and the orders of the BankruptcyCourt. Potential alternatives, to be explored further and evaluated during thereview process, may include a plan of reorganization and investment for futuregrowth, and/or the licensing, sale or divestiture of some, or all, of thecompany's proprietary technologies.

There can be no assurance that the exploration of strategicalternatives will result in any agreements or transactions, or as to the timingof any such agreements or transactions.

About Nuvo

Nuvo is leading a transformation in pregnancy care byproviding clinicians and expectant mothers with access to medically-necessaryremote pregnancy monitoring anytime, anywhere. Nuvo’s INVU™ platform is anFDA-cleared remote pregnancy monitoring and management system. It enables thedelivery of remote non-stress tests (NSTs) and maternal and fetal heart ratemonitoring, while pioneering new data-driven personalized pathways that Nuvobelieves can improve future health outcomes. INVU is being used by leadinghealth providers and research institutions across the US and Israel. Nuvo plansto continue to expand the footprint of sales in the US and Israel and plans tointroduce its INVU platform in Europe in 2025, subject to granting of the CEmark, to provide remote access and insights not previously deemed possible.Nuvo is led by a diverse team of experienced business, medical and technologyleaders, united in the mission of breaking down barriers to pregnancy care togive every life a better beginning. For more information and completeindications, contraindications, warnings and precautions, and instructions foruse, visit www.nuvocares.com.

About Intrepid

Intrepid is a specialty investment bank focusing on M&A,capital advisory, special situation, and buy-side search services for middlemarket companies. Its entrepreneurial roots, combined with MUFG (Mitsubishi UFJFinancial Group), one of the largest financial institutions in the world,unlocks the best of both worlds for our clients: human-centric investmentbanking at a global scale. ​Ourunique culture attracts, develops, and retains the best talent in the industry.Through client-centered deal making, best-in-class market intelligence, globalcapital resources, and extensive access to acquirers and capital providers, itsbankers work tenaciously to deliver the value in each business beyondconventional metrics. For more information, visit: https://intrepidib.com/

Forward-Looking Statements

Certain statements contained in this press release may beconsidered forward-looking statements within the meaning of the U.S. PrivateSecurities Litigation Reform Act of 1995, Section 27A of the Securities Act andSection 21E of the Exchange Act. Forward-looking statements generally includestatements that are predictive in nature and depend upon or refer to futureevents or conditions, and include words such as “may,” “will,” “should,”“would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,”“project,” “intend,” and other similar expressions among others. Statementsthat are not historical facts are forward-looking statements. Forward-lookingstatements are based on current beliefs and assumptions that are subject torisks and uncertainties and are not guarantees of future performance. Actualresults could differ materially from those contained in any forward-lookingstatement as a result of various factors, including, without limitation: (i)the possibility that other anticipated benefits of the business combinationwill not be realized; (ii) changes in general economic and/or industry specificconditions; (iii) the ability of Nuvo to retain, attract and hire keypersonnel; (iv) potential adverse reactions or changes to relationships withcustomers, employees, suppliers or other parties resulting from the completionof the business combination; (v) legislative, regulatory and economicdevelopments; (vi) unpredictability and severity of catastrophic events,including, but not limited to, acts of terrorism, outbreak of war orhostilities and any epidemic, pandemic or disease outbreak (includingCOVID-19), as well as management’s response to any of the aforementionedfactors; and (vii) other risk factors as detailed in the registration statement(File No: 333-274803) on Form F-4 filed by Nuvo with the SEC in connection withthe business combination and the prospectus/proxy statement contained therein,as well as those risk factors detailed from time to time in Nuvo’s reportsfiled with the SEC, including its Annual Report on Form 20-F and otherdocuments filed with the SEC. The foregoing list of important factors is notexhaustive. Except as required by applicable law, Nuvo does not undertake anyobligation to revise or update any forward-looking statement, or to make anyother forward-looking statements, whether as a result of new information,future events or otherwise.

‍

Dr. Kyle McMorries at the team at Nacodoches Women's Center (NWC) share their thoughts on how Nuvo's remote NST solution is helping their practice and patients. Here are a few quotes:

“We’re able to decrease latency and increase throughput because NST’s are out of the office in a more comfortable place for the patient.” - Dr. Kyle McMorries

“More than anything, Nuvo gives me peace of mind.” - NWC patient using Nuvo

"I can't imagine our practice without using INVU." - Alisa King, BSN, RN, CLC

Check out the full video here:

Transcript:

Dr. McMorries: We started to offer Nuvo to our patients in response to a lot of changes that were occurring geographically. We're in rural East Texas and several of the outlying hospitals that we're offering maternity services have shut down and for a lot of our patients that means they're 45 minutes to an hour and a half from the nearest delivering facility or maternal prenatal care center. 

Patient (Chelsea): I would have had to move to Nacogoches. I had not experienced pregnancy and anxiety ever before, like I just you got the blue lines and you're excited and that was it like you had a baby like you didn't have to worry about anything bad happening. So after we lost her I was very very very worried about him and just constantly worried that something was going to go wrong and so the minute that they did let me have the (Nuvo) monitor it helped so much.

Patient (Felicia): Really more than anything it gives me a piece of mind being a high-risk pregnancy. Kyle had talked to me about how often I would have to monitor the baby and so working full-time, Nuvo was an option where I could use it at work or at home and I wouldn't have to drive. I live an hour away from the clinic so I wouldn't have to drive an hour to be able to monitor the baby as much. 

Nurse (Alisa): It was very very nice for me personally as the nurse that was doing all of the NST’s. It allowed me to monitor eight patients at one time in a one hour period as opposed to having eight patients sprinkled all throughout the day and then that was that was the day and it would take up exam rooms and so for me personally it's been great. It's been good for the provider too because then that's not an exam room that's being used.

Dr. McMorries: The recommendation for Nuvo to other practices is two thumbs up and I would say as an office it's been extremely positive because of decreasing the latency of our rooms we're basically able to increase our throughput because of that (NST’s) being out of the office into a more comfortable place for the patient, so overall it's a very positive experience we very much recommend it. 

Nurse (Alisa): Honestly, I can't say enough positive things about it. We're going on 2 years and I can't imagine our practice without using INVU.

‍

Nacogdoches Women's Center has fully integrated Nuvo into their practice and conducts nearly all of their NST's remotely using the INVU by Nuvo platform. This has improved staff efficiency and patient satisfaction, while cost-effectively increasing revenue to their practice.

"The biggest impact I've seen is that we freed up space in the office so that we're able to see patients that have problems or more acute issues." - Dr. Kyle McMorries

Check out the full video here:

‍

Transcript: 

Dr. Kyle McMorries: Nuvo has had a positive financial impact on our practice in a couple of ways. The main benefit we've seen is by keeping patients at home, keeping patients happy and being able to reach patients who are particularly high-risk in areas that are further away from our office. We've seen upticks in the number of patients that we've been able to attract from those different markets. The biggest impact I've seen is that we freed up space in the office so that we're able to see patients that have problems or more acute issues.

‍

Nacogdoches Women's Center has fully integrated Nuvo into their practice and conducts nearly all of their NST's remotely using the INVU by Nuvo platform. This has improved staff efficiency and patient satisfaction, while cost-effectively increasing revenue to their practice.

"I have to admit as a labor and delivery nurse I was a little skeptical at first because I thought “how is a patient going to monitor themselves at home”, but I have been shocked and amazed at how amazing it has worked, even better than our NST machine in the office when we have to use it." - Alisa King, OB nurse at Nacogdoches Women's Center.

Check out the full video here: 

We are pleased to share this short testimonial video from Deb Henretta, C-suite level executive and former head of Proctor & Gamble's global baby care business, sharing her perspective on the value Nuvo brings to patients and pregnancy care.

Nuvo gives patients the ability to attend NST appointments from wherever they need to be - at home, at work, or anywhere else. NWC patient, Felicia, shares her experience as a patient using Nuvo:

"My experience with Nuvo has been super easy so it's been very convenient for me to use it at work." - Felicia, NWC patient using Nuvo

"It's a great patient pleaser!" - Dr. Kyle McMorries

Check out the full video here: 

Transcript:

Patient (Felicia): My experience with Nuvo has been super easy so it's been very convenient for me to use it at work. I just shut my office door get it hooked up and then I can you know cover my belly back up and I can sit at my computer and still do all of my paperwork and stuff and even have meetings and things and people never even know that I'm monitoring.

Dr. Kyle McMorries: It's a great patient pleaser! Every patient we have on it loves the fact that they're not having to miss work, they're not having to drive in, they're not having to go through parking, checkin, and all the processes. Overall it's a very positive experience and we very much recommend it.

‍

Following Nuvo’s NASDAQ Listing, Addition of Machado Brings StrongHealth and Impact Experience to Remote Pregnancy Monitoring Pioneer

TELAVIV, Israel – May 9, 2024 – Holdco Nuvo Group D.G Ltd (NASDAQ: NUVO)(“Nuvo”), a pioneer in remote pregnancy monitoring, today announced the expansion of its board of directors with the addition of Adriana Machado, who will help guide Nuvo’s mission of addressing health disparities and social determinants of care through its advanced pregnancy monitoring technology.

“We are delighted to welcome Adriana to Nuvo’s board,” said Rice Powell, CEO of Nuvo. “She will provide a substantial health innovation perspective and female leadership that supports our mission. Adriana is also a true advocate for transformation and health equity, and we look forward to working with her to expand our efforts and market impact.”

Machado brings three decades of experience in business leadership, strategic planning and international relations. A celebrated business leader in Latin America, she was the first female CEO of GE Brazil, and is Founder of the Briyah Institute, aBenefit Corporation (B Corp) that ignites leaders to transform organizations by applying systems thinking to business. Ms. Machado holds board positions with various health and civil society organizations and, in 2013, was recognized by Forbes as one of the 10 most powerful businesswomen in Brazil.

"I am excited to join Nuvo’s board of directors at such a pivotal time in the Company's development,”said Adriana Machado. “I look forward to bringing my experience of the international health innovation landscape to help the Company improve access to care for expectant mothers across the globe.”

###

About Nuvo

Nuvo is leading a transformation in pregnancy care by providing clinicians and expectant mothers with access to medically-necessary remote pregnancy monitoring anytime, anywhere. Nuvo’s INVU™ platform is an FDA-cleared remote pregnancy monitoring and management system. It enables the delivery of remote non-stress tests(NSTs) and maternal and fetal heart rate monitoring, while pioneering new data-driven personalized pathways that Nuvo believes can improve future health outcomes. INVU is being used by leading health providers and research institutions across the US and Israel. Nuvo plans to continue to expand the footprint of sales in the US andIsrael and plans to introduce its INVU platform in Europe in 2024, subject to granting of the CE mark it filed in Europe in March 2023, to provide remote access and insights not previously deemed possible. Nuvo is led by a diverse team of experienced business, medical and technology leaders, united in the mission of breaking down barriers to pregnancy care to give every life a better beginning. For more information and complete indications, contraindications, warnings and precautions, and instructions for use, visit www.nuvocares.com.

Forward-LookingStatements

Certain statements contained in this press release may be considered forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of1995, Section 27A of the Securities Act and Section 21E of the Exchange Act.Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,”“likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: (i) the possibility that other anticipated benefits of the business combination will not be realized; (ii)changes in general economic and/or industry specific conditions; (iii) the ability of Nuvo to retain, attract and hire key personnel; (iv) potential adverse reactions or changes to relationships with customers, employees, suppliers or other parties resulting from the completion of the business combination;(v) legislative, regulatory and economic developments; (vi) unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism, outbreak of war or hostilities and any epidemic, pandemic or disease outbreak (including COVID-19), as well as management’s response to any of the aforementioned factors; and (vii) other risk factors as detailed in the registration statement(File No: 333-274803) on Form F-4 filed by Nuvo with the SEC in connection with the business combination and the prospectus/proxy statement contained therein, as well as those risk factors detailed from time to time in Nuvo’s reports filed with the SEC, including its Annual Report on Form 20-F and other documents filed with the SEC. The foregoing list of important factors is not exhaustive. Except as required by applicable law, Nuvo does not undertake any obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

‍